Alpha-O Peptides

Alpha-O Peptides are focusing on the development of potent vaccines based on repetitive antigen display technology.

Alpha-O Peptides AG (“AOP”) is a Swiss nano-biotechnology company focusing on the development of potent vaccines based on repetitive antigen display technology using their proprietary and patented self-assembling protein nanoparticles (SAPNs). AOP’s most advanced vaccine has demonstrated complete protection against malaria infection in an animal model. The National Institutes of Health (NIH) and the U.S. Military Infectious Disease Research Program have both supported this project. In addition, a grant from the US Department of Defense was awarded in 2014 to run a phase I/IIa clinical trial at the Walter Reed Army Institute of Research (WRAIR). In 2011, in collaboration with the University of Connecticut and the Kantonsspital St. Gallen, AOP received a 5-year NIH-NIDA award for the development of a nicotine vaccine from preclinical research into clinical trials phase I, which is currently also in GMP production. AOP has further initiated pre-clinical and basic research projects of several other programs targeting cancer and several other infectious diseases.​